BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

In particular, the drug candidate BNT327/PM8002 developed by Biotheus will be a key area of focus after the deal closes. Last ...

BioNTech, the German pharmaceutical company, announced on Wednesday that it has reached an agreement to acquire Biotheus, a Chinese biotechnology fir ...

The German firms is going to obtain the rights to Biotheus’ “investigational bispecific antibody” named the “BNT327/PM8002,” and use it in its oncology strategy. The advanced clinical asset focuses on ...

The acquisition is centered around Biotheus’ main asset, BNT327/PM8002, which works by boosting the immune system to attack ...

Major stock indexes ended Wednesday trading virtually flat after an inflation report showed no surprises for investors.

With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

The acquisition would grant BioNTech full global rights to the promising bispecific antibody BNT327/PM8002, which was ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The deal, which is expected to close in Q1 2025, will give BioNTech (BNTX) full global rights to BNT327/PM8002, a PD-L1 x VEGF-A bispecific antibody that the companies believe has the potential to ...